Add to a list

Inactive Instrument

Acura Pharmaceuticals, Inc. Share Price Nasdaq

US00509L8028

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Acura Pharmaceuticals, Inc.

Market Cap	3.28M 2.87M 2.64M 2.43M 4.61M 315M 4.68M 31.57M 12.39M 154M 12.31M 12.04M 531M	P/E 2020	-5.25x	P/E 2021	-25x
Enterprise Value	3.41M 2.98M 2.75M 2.53M 4.8M 328M 4.88M 32.87M 12.9M 161M 12.82M 12.54M 553M	EV / Sales 2020	2.91x	EV / Sales 2021	20.9x
Free-Float	98.31%	Yield 2020 *	-	Yield 2021	-

* Estimated data More valuation ratios

Latest news : Acura Pharmaceuticals, Inc.

06-23	Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	CI
05-28	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
03-10	Acura Pharmaceuticals, Inc. Receives Loans of $100,000 from Abuse Deterrent Pharma, LLC	CI
03-09	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
12-11	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
04/09/25	Acura Pharmaceuticals, Inc. Announces Loans from Abuse Deterrent Pharma, LLC	CI
02/09/25	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
17/07/25	Acura Pharmaceuticals, Inc. announced that it has received $8.394279 million in funding from Abuse Deterrent Pharma, LLC	CI
19/06/25	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
30/05/25	Acura Pharmaceuticals, Inc. Announces License, Development and Commercialization Agreement with AD Pharma	CI
30/05/25	Acura Pharmaceuticals, Inc. Amends Amend the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note with AD Pharma	CI
21/05/25	Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Announces Second Meeting with US Food and Drug Administration	CI
23/04/25	Acura Pharmaceuticals, Inc. Receives Loan from Abuse Deterrent Pharma, LLC	CI

More news

Press Releases: Acura Pharmaceuticals, Inc.

16/12/24	Acura Pharmaceuticals : Financial Obligation Form 8 K	PU
26/07/24	Acura Pharmaceuticals : New Financial Obligation Form 8 K	PU
26/03/24	Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	PU
21/12/23	Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	PU
06/12/23	Acura Pharmaceuticals : New Financial Obligation - Form 8-K	PU

More press releases

Managers and Directors: Acura Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Jones CEO	Chief Executive Officer	67	31/03/2011
Bob Seiser DFI	Director of Finance/CFO	62	31/07/2024
Albert Brzeczko CTO	Chief Tech/Sci/R&D Officer	69	31/01/2009

Director	Title	Age	Since
William Skelly CHM	Chairman	75	30/09/1996
Immanuel Thangaraj BRD	Director/Board Member	55	30/11/2002
Bruce Wesson BRD	Director/Board Member	83	28/02/1998

More insiders

Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACURA PHARMACEUTICALS, INC.	-.--%	+4.44%	-	-	6.66K
ARGENX SE	-1.39%	-6.15%	+56.05%	+71.53%	54.49B
WUXI APPTEC CO., LTD.	+3.13%	+11.16%	+67.30%	+94.35%	55.93B
INSMED INCORPORATED	-0.82%	-6.35%	+6.09%	+427.20%	23.87B
BIONTECH SE	+0.16%	-3.35%	-18.30%	-15.68%	22.86B
WUXI BIOLOGICS (CAYMAN) INC.	+3.51%	+7.50%	+47.81%	-3.33%	20B
GENMAB A/S	+1.94%	+0.21%	+39.31%	-29.41%	17.48B
PHARMAESSENTIA CORPORATION	+10.00%	-2.06%	+210.10%	+370.99%	15.39B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.69%	+4.38%	+56.51%	+712.88%	15.19B
EXELIXIS, INC.	-0.35%	-0.57%	+26.62%	+190.72%	14.02B
Average	+2.42%	+0.34%	+54.61%	+202.14%	26.58B
Weighted average by Cap.	+1.93%	+0.47%	+52.90%	+157.36%

	2020	2021
Net sales	3.57M 3.12M 2.88M 2.65M 5.02M 344M 5.1M 34.37M 13.49M 168M 13.41M 13.11M 579M	1.56M 1.37M 1.26M 1.16M 2.2M 150M 2.23M 15.05M 5.91M 73.51M 5.87M 5.74M 253M
Net income	-1.21M -1.06M -974K -896K -1.7M -116M -1.73M -11.63M -4.56M -56.81M -4.54M -4.44M -196M	-879K -769K -709K -652K -1.23M -84.58M -1.26M -8.46M -3.32M -41.34M -3.3M -3.23M -142M
Net Debt	5.86M 5.12M 4.72M 4.34M 8.23M 563M 8.37M 56.39M 22.12M 275M 21.99M 21.51M 949M	135K 118K 109K 100K 190K 12.99M 193K 1.3M 510K 6.35M 507K 496K 21.88M

Acura Pharmaceuticals, Inc. Share Price Nasdaq

Stocks

US00509L8028

Biotechnology & Medical Research

Valuation: Acura Pharmaceuticals, Inc.

Latest news : Acura Pharmaceuticals, Inc.

Press Releases: Acura Pharmaceuticals, Inc.

Managers and Directors: Acura Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile